Down-regulation of a novel form of fibroblast growth factor receptor 1 in human breast cancer
Monoclonal antibodies against two epitopes of FGFR-1 have been used to investigate FGFR-1 expression in the normal and neoplastic human breast. Different forms are detected in the different cell types constituting the normal breast. Moreover, breast cancer cells lack one form of FGFR-1. Western blot analysis showed 115-kDa and 106-kDa forms of FGFR-1 within the human breast. The 115-kDa band corresponds to the beta form of FGFR-1, whereas the 106-kDa band is truncated at the carboxyl terminus. The 106-kDa form of FGFR-1 is the major form present in breast fibroblasts and myoepithelial cells, whereas epithelial cells contain equal amounts of the 115-kDa and 106-kDa forms. Breast cancer cells, however, appear to contain only the 115-kDa form of FGFR-1. This expression pattern is reflected in malignant and non-malignant tissue samples. Using reverse transcription polymerase chain reaction (RT-PCR) analysis, we have shown that the 106-kDa FGFR-1 isoform is not the previously described alpha 2 receptor that arises from a 25-base pair insertion in the second kinase domain. It is probable that the 106-kDa FGFR-1 has different signalling properties to the full-length receptor, having lost at least one tyrosine at amino acid 766, which is required for phospholipase C activation. This form of FGFR-1 appears to be lost in all breast cancer cells analysed and its absence may have a bearing on malignancy.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1997 |
|---|---|
| Erschienen: |
1997 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:76 |
|---|---|
| Enthalten in: |
British journal of cancer - 76(1997), 11 vom: 26., Seite 1419-27 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yiangou, C [VerfasserIn] |
|---|
| Anmerkungen: |
Date Completed 08.01.1998 Date Revised 15.05.2019 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM093446837 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM093446837 | ||
| 003 | DE-627 | ||
| 005 | 20231222093620.0 | ||
| 007 | tu | ||
| 008 | 231222s1997 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0312.xml |
| 035 | |a (DE-627)NLM093446837 | ||
| 035 | |a (NLM)9400937 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yiangou, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Down-regulation of a novel form of fibroblast growth factor receptor 1 in human breast cancer |
| 264 | 1 | |c 1997 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 08.01.1998 | ||
| 500 | |a Date Revised 15.05.2019 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Monoclonal antibodies against two epitopes of FGFR-1 have been used to investigate FGFR-1 expression in the normal and neoplastic human breast. Different forms are detected in the different cell types constituting the normal breast. Moreover, breast cancer cells lack one form of FGFR-1. Western blot analysis showed 115-kDa and 106-kDa forms of FGFR-1 within the human breast. The 115-kDa band corresponds to the beta form of FGFR-1, whereas the 106-kDa band is truncated at the carboxyl terminus. The 106-kDa form of FGFR-1 is the major form present in breast fibroblasts and myoepithelial cells, whereas epithelial cells contain equal amounts of the 115-kDa and 106-kDa forms. Breast cancer cells, however, appear to contain only the 115-kDa form of FGFR-1. This expression pattern is reflected in malignant and non-malignant tissue samples. Using reverse transcription polymerase chain reaction (RT-PCR) analysis, we have shown that the 106-kDa FGFR-1 isoform is not the previously described alpha 2 receptor that arises from a 25-base pair insertion in the second kinase domain. It is probable that the 106-kDa FGFR-1 has different signalling properties to the full-length receptor, having lost at least one tyrosine at amino acid 766, which is required for phospholipase C activation. This form of FGFR-1 appears to be lost in all breast cancer cells analysed and its absence may have a bearing on malignancy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Receptors, Fibroblast Growth Factor |2 NLM | |
| 650 | 7 | |a FGFR1 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor Protein-Tyrosine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Receptor, Fibroblast Growth Factor, Type 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Cox, H |e verfasserin |4 aut | |
| 700 | 1 | |a Bansal, G S |e verfasserin |4 aut | |
| 700 | 1 | |a Coope, R |e verfasserin |4 aut | |
| 700 | 1 | |a Gomm, J J |e verfasserin |4 aut | |
| 700 | 1 | |a Barnard, R |e verfasserin |4 aut | |
| 700 | 1 | |a Walters, J |e verfasserin |4 aut | |
| 700 | 1 | |a Groome, N |e verfasserin |4 aut | |
| 700 | 1 | |a Shousha, S |e verfasserin |4 aut | |
| 700 | 1 | |a Coombes, R C |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, C L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 76(1997), 11 vom: 26., Seite 1419-27 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:76 |g year:1997 |g number:11 |g day:26 |g pages:1419-27 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 76 |j 1997 |e 11 |b 26 |h 1419-27 | ||